January 11, 2021

Chart of the Week: The early success story of Israel’s vaccination programme

by Fathom Consulting.

Refresh this chart in your browser | Edit the chart in Datastream

As many advanced economies start their programmes of vaccinations against COVID-19, Israel stands out as an example of effective and rapid distribution of doses among its population. Having, at great expense, precured an early and large quantity of the Pfizer/BioNTech vaccine, by the end of last week Israel had given 20% of its population at least one dose of the vaccine. That is a significantly higher proportion than any other country. Among advanced economies, the US is next in line — 2% of the population has received at least one dose.

The US has been criticised for its slower than expected roll out of COVID-19 vaccines, having missed a target set by the Trump administration of vaccinating 20 million Americans by the end of 2020. Reasons given for the slow roll out include logistical issues getting doses to patients and the requirement to train medical staff.

The UK, which approved a third vaccine by green-lighting the Moderna vaccine last week, has also been criticised for excessive red tape in the vaccination process and difficulties getting staff into care homes to vaccinate the elderly.

Join a growing community of asset managers and stay up to date with the latest research from Refinitiv and partners to help you inform your investment decisions. Follow our Asset Management LinkedIn showcase page.

________________________________________________________________________________________

Refinitiv Datastream

Financial time series database which allows you to identify and examine trends, generate and test ideas and develop view points on the market.

Refinitiv offers the world’s most comprehensive historical database for numerical macroeconomic and cross-asset financial data which started in the 1950s and has grown into an indispensable resource for financial professionals. Find out more.

Article Keywords ,

Get In Touch

Subscribe

We have updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.×